Replies to post #799274 on NorthWest Biotherapeutics Inc (NWBO)

[Smitty5150]

So NWBO would invest about $15 million in C lab manual production and then just discard that investment to save nine months,

You are ignoring the fact the NW is already set-up with B rooms, completed, certified and ready to go. They spent a considerable amount of money to do so. Nobody is ignoring the fact that Flaskworks/Eden is the future. The UK MAA can be updated at any time, it does not have to be now. The Type B variation can be submitted once everything is in place adn AFTER the current MAA is approved. I confirmed this with the MHRA. Alex told me companies do this all the time and the average turn-around is about 90 days, although some go longer depending on complexity. Facts are facts...DCVax can be approved under the current MAA, and a type B variation can be applied for at any time once all the ducks are lined up. You are acting like this is the ONLY time they can submit to accommodate a update with the way DCVax is manufactured. This is clearly not the case.

[bas2020]

Hey densedave, your reading comprehension needs some attention...

The company said it will transition to the C-lab suites... which means it will begin with the existing manufacturing method upon approval. It's not saying it will wait for the C-lab suites to begin.

“The Company views use of the Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites… and views such transition as central to large-scale commercial production.”